Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04687865
Recruiting Observational

Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)

NCT04687865 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2020-01-08
Last updated
2025-03-07

Condition(s) studied

Organ Transplantation

Investigational drug(s) / intervention(s)

Biobank

Biobank: For each patient included in the study the following samples will be collected at the indicated time points after transplantation: * Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy. * Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy. * Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy. * Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction.

Study summary

This study aims to constitute a collection of biological materials from in transplant patients and to provide biological materials from transplanted patients in order :

i) validate new theory on the cause of allograft loss, ii) develop innovative biomarker for rejection and other transplantation-related conditions (such as BK virus nephropathy, Post-transplant lymphoproliferative disorder ( PTLD) ...)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or Female patient ≥18 years old * Recipient of an organ transplant * Written informed consent Exclusion Criteria: * Non-affiliation to a social security system. * Subjects deprived of liberties * Pregnant or breastfeeding woman

Primary outcome measure(s)

  • the biological samples — At inclusion
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 1
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 3
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 6
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 12
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 60
    The goal of this study is to provide biological materials from transplanted patients
  • Change Biological Samples — Month 120
    The goal of this study is to provide biological materials from transplanted patients

Trial sites (1)

FacilityCityRegionStatus
Hopital Edouard Herriot Lyon Rhône Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Other trials for the same condition

Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management Recruiting
Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04687865 on ClinicalTrials.gov ↗ ← All trials in France